Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 255.17 M

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Shareholders' Equity is USD 255.17 M for the year ending December 31, 2023, a -42.42% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 443.14 M, a -8.25% change year over year.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 482.97 M, a 10.71% change year over year.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 436.25 M, a 11.90% change year over year.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 389.86 M, a 6.71% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
SV Wall Street
Shenzhen Stock Exchange: 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

CEO Ms. Hao Cai
IPO Date Aug. 19, 2011
Location China
Headquarters Zhengding County High-tech Ind Dev Zone
Employees 1,410
Sector Healthcare
Industries
Pharmaceuticals 3D Printing Biotechnology Cement Chemicals & Advanced Materials Composite Materials Construction Materials Fertilizers Plastics
Description

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China. Its products include crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadra Heparin calcium raw materials, nadroparin calcium injections, and dalteparin sodium raw materials and injections. The company was founded in 2000 and is based in Shijiazhuang, China.

StockViz Staff

February 3, 2025

Any question? Send us an email